Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.

@article{Bretton1989IntravesicalBC,
  title={Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra.},
  author={Philippe Bretton and Harry W. Herr and Willet F. Whitmore and Robert A. Badalament and Marek Kimmel and John Provet and Herbert Friedrich Oettgen and Myron R. Melamed and William R. Fair},
  journal={The Journal of urology},
  year={1989},
  volume={141 4},
  pages={
          853-6
        }
}
A total of 23 patients presenting with multifocal superficial bladder cancer and concomitant in situ transitional cell carcinoma of the prostatic urethra (mucosal in 19 and ductal in 4) underwent transurethral resection and intravesical bacillus Calmette-Guerin therapy. Median followup was 51.6 months (range 6 to 105 months). Of the 23 patients 13 (48 per cent) had a complete response with a median followup of 43.7 months without recurrence. Progression of some type (local, muscle invasion or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Carcinoma in situ and treatment options

M. Erton, Y. Ilker, A. Akdaş
  • International Urology and Nephrology
  • 1996
VIEW 1 EXCERPT
CITES BACKGROUND